Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

EVO301

Other · developed by Evommune

Phase 2 Most advanced trial (none active)
EVMN Developer
1 Registered trials

What is EVO301?

EVO301 is a drug studied in atopic dermatitis (eczema).

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Dermatology
Developer
Evommune, Inc. (EVMN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06723405 Phase 2 Atopic Dermatitis (AD) Completed EVMN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Atopic Dermatitis (AD)EczemaEczema Atopic Dermatitis

More from Evommune

EVO101 Phase 2 EVO756 Phase 2

Follow EVMN, the company behind EVO301

See EVMN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

EVMN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.